Navigation Links
Luminex Corporation Reports First Quarter 2012 Results

AUSTIN, Texas, April 30, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced financial results for the first quarter ended March 31, 2012.  Financial and operating highlights include the following:

  • Consolidated first quarter revenue was $48.7 million, a 13 percent increase over the first quarter of 2011
  • First quarter assay revenue was $17.3 million, a 80 percent increase over the first quarter of 2011
  • First quarter shipments of 206 multiplexing analyzers that included 55 MAGPIX® systems, resulting in cumulative life-to-date multiplexing analyzer shipments of 8,884, up 12 percent from a year ago
  • Consolidated gross profit margin was 69 percent for the first quarter of 2012
  • Operating expenses for the first quarter of 2012 were $28.2 million, an increase of $5.7 million over the first quarter of 2011. $2.1 million of this increase can be attributed to Luminex Madison, formerly known as EraGen Biosciences, that was acquired on June 27, 2011
  • Operating income for the first quarter of 2012 was $5.6 million compared with operating income of $8.3 million for the same period last year
  • Extended a global sales and distribution agreement with Bio-Rad Laboratories, Inc. (NYSE: BIO) under which Luminex has granted Bio-Rad global sales and distribution rights for Luminex's MAGPIX multiplexing analyzer and extended the strategic partnership agreement until 2023
  • Received CE marking for the newborn screening assay, xMAP® NeoPlex4™, and a fully automated instrument, the NeoPlex System, in April
  • (Logo:

    (in thousands, except percentages) Three Months EndedMarch 31,Variance20122011($)(%)(unaudited)System sales

    (681)-9%Consumable sales

    11,90015,002(3,102)-21%Royalty revenue

    8,2427,25698614%Assay revenue

    17,2979,5847,71380%All other revenue

    5,45213%"Luminex delivered a solid financial and operating performance for the first quarter of 2012," said Patrick J. Balthrop, president and chief executive officer of Luminex.  "Our assay category showed excellent growth, driven by continued execution in our core assay franchises such as our xTAG® Cystic Fibrosis product line, growing demand outside the U.S. for our innovative xTAG Gastrointestinal Pathogen Panel (GPP), and a strong contribution from Luminex Madison. As expected, consumable revenue in the first quarter faced a difficult year-over-year comparison, yet grew 18% sequentially. In addition, we continue to grow our installed base at a healthy rate and are pleased to have expanded our distribution partners for our MAGPIX system with the addition of Bio-Rad Laboratories announced in early April." 

    "Regarding new product initiatives, I am pleased to report that Luminex has received CE Marking for its NeoPlex4 assay and fully automated NeoPlex system. This product offering addresses a sizeable new market opportunity for Luminex and we are excited about the clear advantages offered to the public health lab customer," added Balthrop. "NeoPlex4 is another example of how Luminex provides advanced solutions and real value to our customers. With new assays like GPP, NeoPlex4 and the exciting portfolio from Luminex Madison, we are positioned for continued strong growth in the future," Balthrop concluded. 

    "While we are pleased that both reportable segments achieved GAAP profitability in the first quarter of 2012, we experienced a decline in total operating income year-over-year primarily as a result of two factors," said Harriss T. Currie, vice president and chief financial officer. "First, we experienced a normalization in bulk consumable purchase behavior from a top partner, as anticipated; and second, operating expenses for the current quarter included $2.1 million attributable to our Luminex Madison location.  That transaction closed on June 27, 2011.  Sequentially, our operating expenses actually declined slightly from the fourth quarter of 2011.  We remain on-track to recognize accretion from the Luminex Madison transaction in 2012 and expect to face improving year-over-year consumable revenue comparisons in the second half of 2012."LUMINEX CORPORATION
    (in thousands, except percentages) Three Months EndedMarch 31,Variance20122011($)(%)(unaudited)RevenueTechnology and strategic partnerships

    (1,726)-5%Assays and related products

    18,51811,3407,17863%Total Revenue

    48,72743,2755,45213%Operating income (loss)Technology and strategic partnerships

    4,1998,656(4,457)-51%Assays and related products

    1,409(362)1,771489%Total Operating income

    5,6088,294(2,686)-32%FINANCIAL OUTLOOK AND GUIDANCE The Company reaffirms its 2012 annual revenue guidance of between $205 and $215 million.

    CONFERENCE CALL Management will host a conference call to discuss the operating highlights and financial results for the first quarter ended March 31, 2012, on Monday, April 30, 2012, at 4:00 p.m. Central time/ 5:00 p.m. Eastern time.  The conference call will be webcast live and will be accompanied by a slide presentation, both of which may be accessed at Luminex Corporation's website at  Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the call to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the call and slides will be archived for six months on the website using the 'replay' link.

    Luminex develops, manufactures and markets proprietary biological testing technologies with applications throughout the life sciences industry.  The Company's xMAP system is an open-architecture, multi-analyte technology platform that delivers fast, accurate and cost-effective bioassay results to markets as diverse as pharmaceutical drug discovery, clinical diagnostics and biomedical research, including the genomics and proteomics research markets.  The Company's xMAP technology is sold worldwide and is in use in leading research laboratories as well as major pharmaceutical, diagnostic and biotechnology companies.  Further information on Luminex or xMAP can be obtained on the Internet at

    Statements made in this release that express Luminex's or management's intentions, plans, beliefs, expectations or predictions of future events are forward-looking statements. Forward-looking statements in this release include statements regarding: the expansion of our installed base; expanded distribution for our MAGPIX system, including distribution by Bio-Rad Laboratories; the development progress of our assay products, including NeoPlex4 and NeoPlex System; anticipated FDA clearance of our products, including Gastrointestinal Pathogen Panel, NeoPlex4 and NeoPlex System;  market acceptance of our products, including Gastrointestinal Pathogen Panel, NeoPlex 4 and NeoPlex System, Cystic Fibrosis and RVP FAST assay product; status of integration of Luminex Madison; the ability of our investment in current initiatives and new products to deliver high performance solutions, and drive long-term value for our shareholders; and, projected 2012 revenue. The words "believe," "expect," "intend," "estimate," "anticipate," "will," "could," "should" and similar expressions are intended to further identify such forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  It is important to note that the Company's actual results or performance could differ materially from those anticipated or projected in such forward-looking statements.  Factors that could cause Luminex's actual results or performance to differ materially include risks and uncertainties relating to, among others, market demand and acceptance of Luminex's products and technology, the Company's dependence on strategic partners for development, commercialization and distribution of products, concentration of the Company's revenue in a limited number of strategic partners, fluctuations in quarterly results due to a lengthy and unpredictable sales cycle and bulk purchases of consumables, Luminex's ability to scale manufacturing operations and manage operating expenses, gross margins and inventory levels, potential shortages of components, competition, the timing of regulatory approvals, the implementation, including any modification, of the Company's strategic operating plans, the uncertainty regarding the outcome or expense of any litigation brought against Luminex, risks relating to Luminex's foreign operations, risks and uncertainties associated with implementing our acquisition strategy and the ability to integrate acquired companies, or selected assets into our consolidated business operations, including the ability to recognize the benefits of our acquisitions, as well as the risks discussed under the heading "Risk Factors" in Luminex's Reports on Forms 10-K and 10-Q, as filed with the Securities and Exchange Commission.  The forward-looking statements, including the financial guidance and 2012 outlook, contained herein represent the judgment of Luminex as of the date of this press release, and Luminex expressly disclaims any intent, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in Luminex's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

     LUMINEX CORPORATIONCONDENSED CONSOLIDATED BALANCE SHEETS(in thousands) March 31,December 31,20122011(unaudited)ASSETSCurrent assets:Cash and cash equivalents

    58,282Restricted cash

    1,0071,006Short-term investments

    41,09642,574Accounts receivable, net

    27,03123,016Inventories, net

    24,46324,579Deferred income taxes

    4,8105,991Prepaids and other

    3,6393,529Total current assets

    153,876158,977Property and equipment, net

    24,65525,192Intangible assets, net

    28,38029,437Deferred income taxes

    13,45912,817Long-term investments



    7,0407,310Total assets

    282,647LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

    5,941Accrued liabilities

    7,16011,047Deferred revenue

    4,1414,057Current portion of long term debt

    1,292999Total current liabilities

    18,02822,044Long-term debt

    2,4192,573Deferred revenue


    3,7183,831Total liabilities

    27,56031,792Stockholders' equity:Common stock

    4141Additional paid-in capital

    293,314297,104Accumulated other comprehensive gain

    1,164984Accumulated deficit

    (43,747)(47,274)Total stockholders' equity

    250,772250,855Total liabilities and stockholders' equity

    282,647 LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)Three Months EndedMarch 31,20122011(unaudited)Revenue

    43,275Cost of revenue

    14,96712,547Gross profit

    33,76030,728Operating expenses:Research and development

    9,4407,570Selling, general and administrative

    17,61214,281Amortization of acquired intangible assets

    1,100583Total operating expenses

    28,15222,434Income from operations

    5,6088,294Interest expense from long-term debt

    (59)(83)Other income, net

    57107Income before income taxes

    5,6068,318Income taxes

    (2,079)(3,857)Net income

    4,461Net income per share, basic

    .11Shares used in computing net income per share, basic

    40,91941,239Net income per share, diluted

    .11Shares used in computing net income per share, diluted

    42,80542,305 LUMINEX CORPORATIONCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in thousands)Three Months EndedMarch 31,20122011(unaudited)Cash flows from operating activities:Net income

    4,461Adjustments to reconcile net income to net cash provided by operating activities:Depreciation and amortization

    3,5222,516Stock-based compensation

    2,6432,547Deferred income tax benefit

    5531,325Excess income tax benefit from employee stock-based awards


    23271Changes in operating assets and liabilities:Accounts receivable, net

    (4,013)6,588Inventories, net

    133(586)Other assets

    40(1,022)Accounts payable

    (486)(2,744)Accrued liabilities

    (6,026)(1,786)Deferred revenue

    143(143)Net cash (used in) provided by operating activities

    (29)9,023Cash flows from investing activities:Purchases of available-for-sale securities

    (8,999)(7,046)Maturities of available-for-sale securities

    8,5156,921Purchase of property and equipment

    (1,596)(1,154)Purchase of cost method investment

    -(2,000)Net cash used in investing activities

    (2,080)(3,279)Cash flows from financing activities:Payments on debt

    --Proceeds from issuance of common stock

    657228Payments for stock repurchases

    (5,448)(3,250)Excess income tax benefit from employee stock-based awards

    2972,204Net cash used in financing activities

    (4,494)(818)Effect of foreign currency exchange rate on cash

    151148Change in cash and cash equivalents

    (6,452)5,074Cash and cash equivalents, beginning of period

    58,28289,487Cash and cash equivalents, end of period



    Harriss T. Currie

    Matthew ScaloVice President, Finance and Chief Financial Officer

    Sr. Director, Investor Relations512-219-8020  



    SOURCE Luminex Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Luminex Corporation First Quarter Earnings Release Scheduled for April 30, 2012
    2. Luminex Corporation Reports Fourth Quarter and Full Year 2011 Results
    3. Luminex Corporation Vice President of Biodefense to Speak at DTRAS 2011 CBD S&T Conference
    4. Luminex Corporation Reports Third Quarter 2011 Results
    5. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
    6. Luminex Corporation Third Quarter Earnings Release Scheduled for November 1, 2011
    7. Luminex Corporation Hosts Ninth Annual Planet xMAP Europe in Vienna
    8. Luminex Corporation to Present at Upcoming Investment Conferences In September
    9. Luminex Corporation Reports Second Quarter 2011 Results
    10. Luminex Corporation Receives U.S. FDA Clearance for New, Front Line Respiratory Viral Panel Test
    11. Luminex Corporation Second Quarter Earnings Release Scheduled for August 8, 2011
    Post Your Comments:
    (Date:12/14/2019)... , ... December 13, 2019 , ... ... suffering from gum disease in Chattanooga, TN receive gentle care through ... their practice, Drs. Felts and Randall provide effective gum disease care without the ...
    (Date:12/9/2019)... , ... December 09, 2019 , ... ... optimize healthcare provider savings across purchased services contracts, today announced its latest partnership ... in San Diego County with four acute care hospitals, three specialty hospitals, three ...
    (Date:12/8/2019)... ... 2019 , ... Soterius, Inc., an outsourced service provider with ... MAIA Pharmaceuticals, Inc. (MAIA), a specialty pharmaceutical company focused on development and marketing ... Europe, to support their regulatory strategy and operations for filings in Europe. , ...
    Breaking Medicine Technology:
    (Date:12/14/2019)... ... 13, 2019 , ... Those seeking a youthful makeover can receive the rejuvenating ... Cosmetic dentistry treatments like BOTOX offer North Charleston, SC patients a more youthful appearance ... of cosmetic dentistry treatments to achieve patients’ smile goals. , “The art of ...
    (Date:12/14/2019)... ... December 13, 2019 , ..., a trusted resource for ... in Child Development Degree Programs for 2020. The comprehensive research guide is based ... program is evaluated based on curriculum quality, graduation rate, reputation, and post-graduate employment. ...
    (Date:12/9/2019)... ... December 09, 2019 , ... Representatives with Vigorous Innovations ... for athletes just in time for Christmas. , “We’re very excited about the launched ... and spokesperson for Vigorous Innovations. “The new massage gun can eliminate the fatigue of ...
    (Date:12/9/2019)... ... ... WEDI , the nation’s leading nonprofit authority on the use of health ... the U.S. Department of Health and Human Services (HHS), announced today the election of ... as the re-election of ten previous board members to serve two-year terms. , “The ...
    (Date:12/9/2019)... Texas (PRWEB) , ... December ... ... global leader in innovative solutions that help food and manufacturing companies engage ... Responsibility training program. This turnkey solution helps manufacturers build a cohesive culture ...
    Breaking Medicine News(10 mins):